|
|
Volumn 93, Issue 3, 2013, Pages 239-241
|
|
Imaging of TKI-target interactions for personalized cancer therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXITINIB;
BOSUTINIB;
CARBON 13;
CRIZOTINIB;
DASATINIB;
ERLOTINIB;
ERLOTINIB C 11;
GEFITINIB;
GEMCITABINE;
LAPATINIB;
NILOTINIB;
PAZOPANIB;
SORAFENIB;
SUNITINIB;
TRACER;
UNCLASSIFIED DRUG;
VANDETANIB;
VASCULOTROPIN;
VEMURAFENIB;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BRAIN METASTASIS;
BREAST CANCER;
CANCER THERAPY;
CHRONIC MYELOID LEUKEMIA;
EXON;
HUMAN;
HYPEREOSINOPHILIC SYNDROME;
IN VIVO STUDY;
ISOTOPE LABELING;
KIDNEY CARCINOMA;
LIVER CELL CARCINOMA;
LOEFFLER PNEUMONIA;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MYELODYSPLASTIC SYNDROME;
NONHUMAN;
PANCREAS CANCER;
PERSONALIZED MEDICINE;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
THYROID CANCER;
TREATMENT RESPONSE;
CARBON RADIOISOTOPES;
HUMANS;
INDIVIDUALIZED MEDICINE;
POSITRON-EMISSION TOMOGRAPHY;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
QUINAZOLINES;
|
|
EID: 84874185459
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1038/clpt.2012.242 Document Type: Article |
|
Times cited : (15)
|
|
References (5)
|
